M&A Deal Summary |
|
---|---|
Date | 2013-06-11 |
Target | Rights to Synacthen |
Sector | Life Science |
Buyer(s) | Questcor Pharmaceuticals |
Sellers(s) | Novartis |
Deal Type | Divestiture |
Deal Value | 60M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1990 |
Sector | Life Science |
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company that provides drugs for the treatment of autoimmune and inflammatory disorders.
DEAL STATS | # |
---|---|
Overall | 3 of 3 |
Sector (Life Science) | 2 of 2 |
Type (Divestiture) | 2 of 2 |
Country (United States) | 2 of 2 |
Year (2013) | 2 of 2 |
Size (of disclosed) | 1 of 2 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2013-01-02 |
BioVectra
Charlottetown, Prince Edward Island, Canada BioVectra is a supplier of contract manufacturing services to the global pharmaceutical and biotechnology industry and manufactures active pharmaceutical ingredients (API's), chemical intermediates, and bioprocessing reagents. |
Buy | CA$50M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2019-09-10 |
BioVectra
Charlottetown, Prince Edward Island, Canada BioVectra is a supplier of contract manufacturing services to the global pharmaceutical and biotechnology industry and manufactures active pharmaceutical ingredients (API's), chemical intermediates, and bioprocessing reagents. |
Sell | $250M |
Category | Company |
---|---|
Founded | 1996 |
Sector | Life Science |
Employees | 104,323 |
Revenue | 51.8B USD (2022) |
Novartis is a global healthcare and pharmaceutical enterprise dedicated to advancing medical innovation and enhancing patient well-being. Renowned for its pioneering research and development efforts, Novartis has a comprehensive portfolio encompassing groundbreaking pharmaceuticals, generic medications, biosimilars, and eye care solutions. Novartis was founded in 1996 and is based in Basel, Switzerland.
DEAL STATS | # |
---|---|
Overall | 2 of 7 |
Sector (Life Science) | 2 of 4 |
Type (Divestiture) | 1 of 6 |
Country (United States) | 1 of 2 |
Year (2013) | 1 of 1 |
Size (of disclosed) | 2 of 2 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2012-12-17 |
Vivacta
Sittingbourne, United Kingdom Vivacta Limited is a medical diagnostic company developing proprietary sensors and readers for rapid, point-of-care (PoC) testing. The company is applying piezofilm technology to achieve extremely high sensitivity and wide dynamic range for a new generation of diagnostic products adapted to near-patient testing and has generated an independent intellectual property position comprising over 15 patent families. |
Buy | $90M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2014-02-17 |
CoStim Pharmaceuticals
Boston, California, United States CoStim is is an emerging immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer. |
Buy | - |